Improved Anti-Osteoporosis Potency And Reduced Endometrial Membrane Hyperplasia During Hormone Replacement Therapy With Estrogen-Rgd Peptide Conjugates

Yu Xiong,Ming Zhao,Chao Wang,Heng Wei Chang,Shiqi Peng

DOI: https://doi.org/10.1021/jm070242a

IF: 8.039

2007-01-01

Journal of Medicinal Chemistry

Abstract:To improve the specificity and potency of estrogen replacement therapy therapeutics while also minimizing the side effects such as bone resorption and thickening of the uterine wall, a series of novel estrogen-derived conjugates estradiol-3-RGD, estradiol-17-RGD, and estrone-3-RGD peptides have been prepared. In a mouse model, intraperitoneal (i.p.) administration of these estrogen-RGD peptide conjugates resulted in decreased serum concentrations of calcium and alkaline phosphatase, as well as increased levels of calcium, phosphorus, and minerals in the mouse femur. Furthermore, the anti-osteoporosis action of these conjugates followed a dose-dependent manner and was accompanied with no observable effects on endometrial cell hyperplasia. In addition to all of these compounds exhibiting biological activity when administered by the i.p. route, we were particularly pleased to note that the estradiol-3-RGD and estradiol-17-RGD conjugates were both orally active.